Zymeworks Inc ZYME

US Biotechnology

$26.52 ▼ -1.08% ($-0.29)

Open $26.86

Prev Close $26.81

Day Range $26.23 – $26.88

52W Range $15.81 – $31.34

Market Cap $1.63B

Beta 1.33

EPS (TTM) $-2.01

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-06-24
Shares Out.	71,590,000
Website	zymeworks.com/ ↗
Phone	13022748744
Employees	264
Revenue	$4.6M
Gross Profit	$4.6M
Net Income	-$45.0M
Free Cash Flow	-$120.5M
Total Assets	$397.0M
Total Liabilities	$316.6M
Equity	$80.4M

About Zymeworks Inc

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks Inc is a publicly traded company under the ticker symbol ZYME on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.